Serum EGFR/HER-2 combination predicts poor survival in metastatic breast cancer

摘要: 9613 Background: Epidermal growth factor receptor (EGFR, erbB1) is overexpressed in primary breast cancer and some reports a poor prognostic factor. We previously reported that metastatic patients with elevated pretreatment serum HER-2/neu have decreased response survival. (JCO 21: 1967, 2003). Methods: Pretreatment EGFR was quantified the 1st line phase III letrozole-tamoxifen trial controls using Oncogene Science/Bayer Diagnostics ELISA. Results: Serum from 117 healthy post-menopausal female measured 64.1 ± 13.3 ng/ml (mean SD) (Range 39.5–117.1 ng/ml). Using cutpoint of 44.1 control group (5% non-parametric method), 62/542 (11%) had EGFR. Patients no significant difference objective rate (ORR), clinical benefit (CBR), time to progression (TTP), or treatment failure (TTF) hormone therapy, but did significantly reduced survival ...